Trends in prescribing of anticoagulants in those with CHADS2 ≥2 and CHA2DS2-VASc ≥2, 2007–2010a
| 2007 | 2008 | 2009 | 2010 | |
|---|---|---|---|---|
| Size of sample with atrial fibrillation | 62 146 | 64 524 | 63 533 | 59 804 |
| Number identified with CHADS2 ≥2 | 34 827 | 36 394 | 35 948 | 34 041 |
| Percentage with CHADS2 ≥2 | 56.0 | 56.4 | 56.6 | 56.9 |
| Proportion, % | ||||
| Anticoagulant | 49.7 | 50.3 | 51.2 | 53.0 |
| Antiplatelet | 43.9 | 43.8 | 43.4 | 42.2 |
| Both | 6.0 | 6.3 | 6.5 | 6.5 |
| Neither | 12.4 | 12.1 | 11.9 | 11.3 |
| Number identified with CHA2DS2VASc ≥2 | 52 668 | 54 526 | 53 781 | 50 547 |
| Percentage with CHA2DS2-VASc ≥2 | 84.7 | 84.5 | 84.7 | 84.5 |
| Proportion, % | ||||
| Anticoagulant | 48.0 | 48.7 | 49.3 | 50.7 |
| Antiplatelet | 42.9 | 43.2 | 42.9 | 42.0 |
| Both | 5.7 | 6.0 | 6.2 | 6.1 |
| Neither | 14.7 | 14.1 | 13.9 | 13.4 |
↵a Changes in the proportions treated with anticoagulants were all significant at the P<0.01 level.